| Drug ID: | Drug56 |
|---|---|
| Drug Name: | Nitazoxanide |
| CID: | 41684 |
| DrugBank ID: | DB00507 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT06667934 |
| Molecular Formula: | C12H9N3O5S |
| Molecular Weight: | 307.28 g/mol |
| Isomeric SMILES: | CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-] |
| Synonyms: | NITAZOXANIDE; 55981-09-4; Nitazoxanida; Benzamide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl)-; Nitazoxanidum; Nitazoxanidum [INN-Latin]; Nitazoxanida [INN-Spanish]; 2-(Acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide; NSC 697855; EINECS 259-931-8 |
| Phase 0: | 0 |
| Phase 1: | 10 |
| Phase 2: | 55 |
| Phase 3: | 46 |
| Phase 4: | 8 |
| Description: | Nitazoxanide, also known by the brand name Alinia, is a synthetic nitrothiazolyl-salicylamide derivative and an anti-protozoal agent. It is approved for treatment of infectious diarrhea caused by Cryptosporidium parvum and Giardia lamblia in patients 1 year of age and older. Following oral administration it is rapidly hydrolyzed to its active metabolite, tizoxanide, which is 99% protein bound. Peak concentrations are observed 1?? hours after administration. It is excreted in the urine, bile and feces. Untoward effects include abdominal pain, vomiting and diarrhea. [Wikipedia] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt511 | 41684 | Nitazoxanide | 5315 | PKM | Homo sapiens (human) | None | |
| dt512 | 41684 | Nitazoxanide | 1576 | CYP3A4 | Homo sapiens (human) | None | |
| dt513 | 41684 | Nitazoxanide | 6607 | SMN2 | Homo sapiens (human) | None | |
| dt514 | 41684 | Nitazoxanide | 7157 | TP53 | Homo sapiens (human) | None | |
| dt515 | 41684 | Nitazoxanide | 4864 | NPC1 | Homo sapiens (human) | None | |
| dt516 | 41684 | Nitazoxanide | 4780 | NFE2L2 | Homo sapiens (human) | None | |
| dt517 | 41684 | Nitazoxanide | 4363 | ABCC1 | Homo sapiens (human) | 25622337 | ABCC1 gene SNP affects the susceptibility to nitazoxanide |
| dt518 | 41684 | Nitazoxanide | 367 | AR | Homo sapiens (human) | 25752796 | Nitazoxanide binds to and results in decreased activity of AR protein |
| dt519 | 41684 | Nitazoxanide | 383 | ARG1 | Mus musculus (house mouse) | 38663798 | Nitazoxanide inhibits the reaction [lipopolysaccharides results in decreased expression of ARG1 mrna]|nitazoxanide results in increased expression of ARG1 protein|nitazoxanide results in increased expression of ARG1 mRNA |
| dt520 | 41684 | Nitazoxanide | 468 | ATF4 | Homo sapiens (human) | 19664635 | Nitazoxanide promotes the reaction [EIF2A protein results in increased expression of ATF4 protein]|nitazoxanide results in increased expression of ATF4 protein |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT03441893 | Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis | PHASE1|PHASE2 | ACTIVE_NOT_RECRUITING | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | Ulcerative Colitis|Ulcerative Colitis Exacerbatio… | DIAGNOSTIC_TEST: parasitological diagnostics (cop… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations